SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Metabolic / AmylinResearch peptide

Cagrilintide

aka AM833

Long-acting amylin analog studied in combination with semaglutide for weight loss.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Cagrilintide is a long-acting amylin analog designed for once-weekly dosing, most commonly studied as 'CagriSema' with semaglutide.

Source
  • Investigational pharmaceutical
Forms
  • Subcutaneous injection

Mechanism of action

Activates amylin and calcitonin receptors to slow gastric emptying, increase satiety, and suppress glucagon.

Pathways
  • · Amylin receptor
  • · Calcitonin receptor
  • · Vagal satiety signaling
Hormones
  • · Amylin
  • · Glucagon

How it acts on the body

Amylin is co-secreted with insulin by β-cells and contributes to post-meal satiety and glucose control. Cagrilintide is engineered for weekly dosing and adds an amylin-pathway signal on top of the GLP-1 effect from semaglutide, with additive weight loss in trials.

In CagriSema phase 2 data, combined weight loss reached the high teens in percent after roughly six months, exceeding either agent alone. The combination targets two complementary appetite and glucose pathways simultaneously.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

Amylin signalingIncreases
Long-acting receptor activation.
GlucagonDecreases
Postprandial suppression.
Leptin sensitivityModulates
Indirect via weight loss.

Effects on the body

Decreases
Appetite and food intake
Supports
Postprandial glycemic control

Organ system effects

Digestive / Gut

Slower gastric emptying.

Endocrine

Amylin-axis stimulation.

Liver

Reduced hepatic glucose output via glucagon suppression.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Complementary mechanism to GLP-1 agonists
  • Weekly dosing

Potential side effects

Common
  • · Nausea
  • · Decreased appetite
Rare
  • · Injection-site reactions
Serious
  • · Pancreatitis risk in combination therapy under study

Drug interactions

Insulin
Risk of hypoglycemia when stacked.
moderate

Pairing context

Often combined with
  • Semaglutide
    Studied combination with additive weight loss.
Avoid combining with
  • Personal history of medullary thyroid cancer
    Class-level caution with GLP-1/calcitonin-axis drugs.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.